BioNTech triples vaccine sales

BioNTech company, which produces a Covid-19 vaccine using

mRNA vaccine formula and works on mRNA vaccines for incurable diseases such as cancer and HIV, 3.7 percent in the first 3 months of the year. billion euros in net profit.

Prof. Dr. Uğur Şahin and Dr. Founded by Özlem Türeci, BioNTech announced its financial results for the first quarter of 2022. Announcing a net profit of 1.12 billion Euros in the first quarter of last year, the company announced that it has achieved a net profit of 3.7 billion Euros, with a nearly 3-fold increase this year. The company’s total revenues increased by 211% compared to the same period of 2021 and reached 6 billion 373 billion Euros.

in 2021 Delivering 2.6 billion doses of vaccine and generating a revenue of 19 billion Euros from the vaccine, the company increased its Covid-19 vaccine revenue forecast in 2022 from 13 billion Euros to 17 billion Euros.

2.4 billion dose agreement reached

Partnering with Pfizer in the production of Covid-19 vaccine, BioNTech has signed an agreement with more than 100 countries for the supply of 2.4 billion doses for 2022 and 2022 first announced that a total of 750 million doses of vaccine had been billed by the end of the quarter.

Omicron vaccine laboratory data coming soon

Due to the low efficacy of the Covid-19 vaccine against the Omicron variant, studies on a special version for Omicron are ongoing. It has been announced that laboratory data will be obtained in the coming weeks.